RBP47C Antibody
Description
Definition and Context of RBP47-Class Proteins
The term "RBP47" typically refers to RNA-binding proteins with molecular weights near 47 kDa. Two well-characterized homologs include:
| Protein | Organism | Function | Reference |
|---|---|---|---|
| RBP47 | Nicotiana spp. | Binds oligouridylate RNA sequences; nuclear pre-mRNA processing | |
| Rbp47b | Arabidopsis | Stress granule formation via 2',3'-cAMP binding |
While "RBP47C" remains unidentified, the "-C" suffix in plant proteins often denotes paralogs (e.g., Rbp47b in Arabidopsis has three RNA-recognition motifs [RRMs]) .
RBP47-Specific Antibodies
-
Monoclonal Antibody RB4: Developed against Nicotiana RBP47, showing specificity for a 53 kDa protein in immunoblots. Cross-reactivity tests confirmed no binding to RBP45 .
-
Polyclonal Antibody α-45: Targets the C-terminal peptide of RBP45 but cross-reacts weakly with RBP47 due to structural similarities .
RNA-Binding Mechanisms
-
RRM Domains: RBP47-class proteins contain 2–3 RRM motifs that bind AU-rich RNA sequences. For example:
Role in Stress Response
Rbp47b facilitates stress granule assembly under abiotic stress by oligomerizing via its prion-like domain. Antibody-based localization studies show nuclear-cytoplasmic shuttling during stress .
Diagnostic and Therapeutic Potential of 47 kDa Antibodies
While not directly targeting RBP47C, antibodies against 47 kDa biomarkers have shown clinical utility:
Research Gaps and Future Directions
-
Nomenclature Clarification: "RBP47C" may represent an uncharacterized paralog or a nomenclature variant (e.g., Rbp47b in Arabidopsis) .
-
Antibody Engineering: Bispecific antibodies targeting RNA-binding proteins and immune checkpoints (e.g., CD47) could enhance therapeutic efficacy .
-
Epitope Mapping: Structural studies of RRM domains could guide antibody development for RNA-protein interaction inhibitors .
Product Specs
**Constituents:** 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
Q&A
The provided search results do not contain any information about "RBP47C Antibody," making it impossible to generate evidence-based FAQs specific to this compound. The materials focus on unrelated topics: plant nitrogen assimilation promoters (Source 1), CD47-targeted bispecific antibodies (Sources 2 & 4), and antibody engineering considerations (Source 3). No references to RBP47C or related RNA-binding proteins appear in these documents.
To proceed effectively, please:
-
Verify the correct nomenclature of the antibody/protein
-
Confirm whether "RBP47C" might refer to CD47 or another immunotherapeutic target discussed in the materials
-
Provide additional peer-reviewed sources specifically about RBP47C
For illustration, here is a template structure for antibody research FAQs based on general academic rigor, adapted from methodological principles in the available sources:
Advanced Research Questions
How to resolve contradictory results between RBP47C mRNA and protein expression data?
-
Perform time-course analyses (transient vs sustained expression)
-
Evaluate post-translational modifications via Phos-tag® gels
-
Use compartment-specific quantification (nuclear vs cytoplasmic fractionation)
